Disclosure: Louis J. Aronne, MD, has received grants and consulting fees or honoraria from VIVUS, Inc. He has served as an advisor, board member, and consultant for Amylin Pharmaceuticals Inc., Ethicon Endo-Surgery Inc., GlaxoSmithKline Consumer Healthcare, LP, Novo Nordisk, Orexigen Therapeutics, Inc., VIVUS, Inc., and Zafgen Inc. He has also served as a consultant for Takeda Pharmaceuticals. He has received grants from GI Dynamics, Inc., Novo Nordisk, and Aspire Bariatrics. He owns stocks in CardioMetabolic Support Network LLC, MYOS Corporation, and Zafgen Inc. Thomas Wadden, PhD, has served as a consultant and advisor for VIVUS, Inc. He has participated in clinical trials and has received grants on behalf of the University of Pennsylvania from Merck, Novo Nordisk, NutriSystems, Orexigen Therapeutics, Inc., Weight Watchers, and VIVUS, Inc. He has also served as an advisory board member for Novo Nordisk and Orexigen Therapeutics, Inc. Craig Peterson, MS, is an employee of VIVUS, Inc. David Winslow, MD, has served as an advisor and consultant and has received consulting fees, honoraria, and support for travel to meetings by VIVUS, Inc. He has also participated in clinical studies funded by VIVUS, Inc. Sarah Odeh, BS, CMPP, is an employee of The Lockwood Group. The Lockwood Group provided editorial support for the creation of this manuscript, which was funded by VIVUS, Inc. Kishore M. Gadde, MD, has received grant support and support for travel to meetings by VIVUS, Inc. He has also received grant support and has participated in clinical trials supported by Amylin, Medical University of South Carolina, and VIVUS, Inc. He holds stock in Orexigen Therapeutics, Inc.
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
Version of Record online: 17 OCT 2013
Copyright © 2013 The Obesity Society
Volume 21, Issue 11, pages 2163–2171, November 2013
How to Cite
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S. and Gadde, K. M. (2013), Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity, 21: 2163–2171. doi: 10.1002/oby.20584
Funding agencies: Financial support for the studies and funding for editorial assistance was provided by VIVUS, Inc.
- Issue online: 1 NOV 2013
- Version of Record online: 17 OCT 2013
- Manuscript Accepted: 18 JUL 2013
- Manuscript Revised: 15 JUL 2013
- Manuscript Received: 27 APR 2013
Additional Supporting Information may be found in the online version of this article.
|oby20584-sup-0001-suppinfo01.tif||1284K||Figure S1. LS mean percent weight loss from baseline to week 28 in the ITT-LOCF population. (A) PHEN/TPM ER 15/92 compared with phentermine 15 and topiramate ER 92; (B) PHEN/TPM ER 7.5/46 compared with phentermine 7.5 and topiramate ER 46; and (C) PHEN/TPM ER 7.5/46 compared with phentermine 15 and topiramate ER 92. *P < 0.0001 vs. placebo; †P = 0.0001 vs. phentermine 15; ‡P = 0.0009 vs. topiramate ER 92; §P = 0.0003 vs. phentermine 7.5; ¶P < 0.0001 vs. topiramate ER 46; ||P = 0.0037 vs. phentermine 15; #P = 0.0150 vs. topiramate ER 92. ITT, intention- to-treat; LOCF, last observation carried forward; LS, least-squares; PHEN/TPM ER 15/92, phentermine 15 mg and topiramate extended-release 92 mg; PHEN 15, phentermine 15 mg; TPM ER 92, topiramate extended-release 92 mg; PHEN/TPM ER 7.5/46, phentermine 7.5 mg/topiramate extended-release 46 mg; PHEN 7.5, phentermine 7.5 mg; TPM ER 46, topiramate extended-release 46 mg.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.